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Abstract 
Purpose: To genotype healthy Jordanian population from three different provinces (Amman, Zarqa and 
Irbid) for cytochrome P4502C19 and to identify the allelic distribution of CYP2C19 variants in 
comparison with other findings around the world. 
Methods: Healthy Jordanian volunteers were recruited from government hospitals. Two hundred and 
sixty volunteers were included in the study regardless of sex and age. CYP2C19*2, *3,*4, *5, and *6 
alleles were studied using polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) technique. 
Results: The results show that the Jordanian population tested exhibited 9 genotypes out of the 21 
expected CYP2C19 genotypes. CYP2C19*1/*1 and *2/*2 genotypes were the most prominent in the 
sample population, while CYP2C19*2/*5 was the least prevalent genotype. The frequencies of the 
CYP2C19 variants did not deviate from Hardy-Weinberg equilibrium. Allele frequency of CYP2C19*2 in 
the Jordanian population was statistically different from that found in most Europeans, North and South 
Americans, Africans, and some Asian ethnic communities but not with South-East Asian populations 
(China, Chinese-Taiwanese, and Philippines) and Australian Aborigines.  
Conclusion: The findings of this study confirm the importance of CYP2C19 genotyping prior to drug 
therapy administration to achieve optimal dosage and cost-effective therapy.  
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Individual variation in response to drugs is a 
substantial clinical problem that can be inherited. 
The genetically determined variability in drug 
response defines the research area known as 
pharmacogenetics [1]. 
 
One of the main directions in development of 
pharmacogenetics is identifying genes and allelic 
variants of genes that affect human's response to 
drugs [2]. Polymorphisms of genes encoding 
drug metabolism enzymes, drug transporters, 
and drug receptors, which are involved in drug 
responses, have been reported [3,4]. Genetic 
variation can account for as much as 95 % of 
variability in drug disposition and effect [5]. As 
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the main cause of the variation in drug response, 
attention has focused on genetic polymorphisms. 
Single nucleotide polymorphism (SNP) of DNA 
produces variation in drug response and has 
become a representative research target in 
pharmacogenetics [6]. 
 
It is known that many polymorphisms that 
influence drug response and which probably 
contribute significantly to phenotypic variation in 
drug response have significant allele frequency 
differences among racial or ethnic groups [3,7,8]. 
 
Of all genetic factor that affect drug treatment, 
those affecting the activity of the drug 
metabolizing enzyme cytochrome P450 are 
currently considered the quantitatively most 
important [6]. Humans have been estimated to 
have at least 57 different CYP genes, but the 
major drug metabolizing human P450 genes are 
CYP1A, CYP2B, CYP2C, CYP2D, CYP2E and 
CYP3A [9,10]. The CYP2C19 gene is located 
within a cluster of CYP genes on the 4th band of 
region 2 of the long arm of chromosome 10 
(10q24) [11]. 
 
CYP2C19 exhibits high genetic polymorphism, 
including common defective variants. Single-
base substitutions in the coding sequence lead to 
a splicing defect and premature stop codon, and 
therefore to null function of the enzyme. These 
variants together (CYP2C19*2 and CYP2C19*3) 
are responsible for the majority of the CYP2C19-
related poor metabolism (PM) phenotypes in 
different populations [12].  
 
Pharmacogenetics is a rapidly evolving field and 
a lot of information regarding genetic 
polymorphism is being generated for many ethnic 
groups, particularly Caucasians and Orientals. 
However, data on Arab populations is still 
sparse. There is a need to fill the gaps in 
pharmacogenetics knowledge pertaining to the 
Jordanian population. Thus, the aim of this study 
was to genotype healthy Jordanian people for 
cytochrome P4502C19, to identify the variant 
alleles of CYP2C19 and to compare the results 






Healthy Jordanian volunteers were randomly 
recruited from governmental hospitals of three 
provinces (Amman, Zarqa and Irbid). Two 
hundred and sixty volunteers were included in 
the study regardless of sex and age. All 
volunteers gave their written, informed consent. 
The study was approved by the Institutional 
Review Board (IRB)  [AM/16/13/10/1200085] of 
the Hashemite University, Zarqa, Jordan which 
conforms to the World Medical Association 




Three milliliters of peripheral blood were 
withdrawn on ethylenediaminetetraacetic acid 
EDTA tube from each participant by venous 
puncture. DNA was extracted from 300 µL blood 
using a commercially available kit (Wizard 
Genomic DNA Purification Kit, Promega, 
Madison, USA). The CYP2C19*2, *3,*4, *5, and 
*6 alleles were studied using the PCR-RFLP 
technique. The PCR reactions were carried out in 
a BioRad thermocycler (Mycycler, BioRad, USA). 
All PCR primers are indicated from 5' to 3' end 
and are provided in Table 1. The primers 
sequences were based on published literature 
[14-17]. 
 
The amplification products were then digested 
overnight with the appropriate restriction 
endonuclease (Table 1). The digested PCR 
products were resolved by electrophoresis in 3 % 
agarose gels stained with ethidium bromide. The 
result of the electrophoresis was detected and 
documented using the CSL-MicroDoc and Canon 




The observed genotypes and allele frequencies 
were compared with those expected, in order to 
verify the Hardy-Weinberg equilibrium. Allelic 
frequencies and prevalence were compared 
between Jordanians and other populations using 
the test for differences between proportions. The 
statistical analysis has been performed using 
STATISITCA 7 analysis program (StatSoft Inc., 







The total number of subjects enrolled in the 
current study was 260. One hundred and fifty 
nine of them were females (61.2 %) and the 
other 101 (38.8 %) were males. The age of the 
subjects ranged from 18 to 59 years with a mean 
of 24.1 years. There was no significant difference 
(data not shown) between the mean age of 
females (24.3 years) and males (23.7 years) (p > 
0.05). 
 
Yasin et al 
Trop J Pharm Res, December 2016; 15(12): 2747  
 





































118 bp + 50 bp 
BamHI/ 
175 bp + 96 pb 
PstI/  
167 bp + 28 bp 
BstX/ 
203 bp + 26 bp 
BsmB I/  
490 bp + 185bp 
or 
PstI/ 
483 bp + 192 bp 
*Represents an allelic variant 
 
CYP2C19 genotyping results 
 
DNA extraction, PCR amplification and restricted 
PCR products were performed and recorded for 
all samples. Restriction products of the genomic 
DNA for the CYP2C19 variants (*2, *3, *4, *5 and 
*6) and their respective restriction enzymes were 




The size of PCR amplicons and restriction 
digestion products were similar to what have 
been previously reported (Table 1 and Figure1). 
Genotypic and allelic frequencies for the six 
CYP2C19 variants were determined according to 
the count method (Table 2). 
 
 
Figure 1: Representative gel electrophoresis showing the analysis of CYP2C19 variants. Lane L: 50bp DNA 
molecule marker, lane 1: CYP2C19*2 homozygote; lane 2: CYP2C19*2 heterozygote; lane 3: CYP2C19*3 wild 
typea; lane 4: CYP2C19*3 heterozygote; lane 5: CYP2C19*4 wild type, lane 6: CYP2C19*4 homozygote; lane 7: 
CYP2C19*5 heterozygote, lane 8: CYP2C19*5 wild type; lane 9: CYP2C19*6 wild type; lane 10: CYP2C19*6 
heterozygote. a: Wild type: CYP2C191*/*1;*represents an allelic variant 
 





















































*Represents an allelic variant 
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This study has demonstrated a wide presence of 
CYP2C19*1 allele in 158 unrelated healthy 
Jordanian individuals of which 149 (94.30 %) 
were CYP2C19*1/*1 homozygotes, 2 (1.27 %) 
were CYP2C19*1/*2 heterozygotes and 7 (4.43 
%) were CYP2C19*1/*6 heterozygotes. On the 
other hand, CYP2C19*2 allele was reported in 96 
healthy unrelated Jordanian individuals, of which 
79 (82.29 %) were CYP2C19*2/*2 homozygotes, 
2 (2.08 %) were CYP2C19*1/*2 heterozygotes, 4 
(4.17 %) were CYP2C19*2/*3 compound 
heterozygotes, 4 (4.17 %) were CYP2C19*2/*4 
compound heterozygotes, 1 (1.04 %) was 
CYP2C19*2/*5 compound heterozygote, and 6 
(6.25 %) were CYP2C19*2/*6 compound 
heterozygotes, Furthermore, the study has 
shown the presence of CYP2C19*4/*4 
homozygosity in 8 (3.08 %) individuals. 
Therefore, 104 (40%) individuals – 96 
CYP2C19*2 allele homozygotes and 
heterozygotes (92.31 %) and 8 (7.69 %) 
CYP2C19*4 allele homozygotes – are predicted 
to be poor metabolizers. 
 
In addition, Table 2 shows that the Jordanian 
population tested exhibited nine genotypes out of 
the 21 expected CYP2C19 genotypes. 
CYP2C19*1/*1 and *2/*2 genotypes were the 
most prominent genotypes in the Jordanian 
sample population with a frequency of 0.5731 
and 0.3038, respectively. CYP2C19*2/*5 was the 
least prevalent genotype with a frequency of 
0.0038. Furthermore, Table 2 shows the allelic 
frequencies of the six CYP2C19 variants. 
CYP2C19*1 and *2 were the most dominant 
variants with allelic frequencies of 0.5904 and 
0.3365, respectively. CYP2C19*5 was the least 
dominant variant with an allelic frequency of 
0.0019. The frequencies of the CYP2C19 
variants in the Jordanian population were found 
not to deviate from the Hardy-Weinberg 
equilibrium. 
 
Comparison between Jordanian allelic 
frequencies of CYP2C19*2 and *3 alleles and 
that of other ethnic populations worldwide is 
shown in Table 3 [18,19]. Allele frequency of 
CYP2C19*2 in the Jordanian population was 
statistically different (p < 0.05) from that found in 
most of the European, North and South 
Americans, Africans, and some Asian ethnic 
communities. No significant differences regarding 
the CYP2C19*2 allele frequency were found 
when comparing Jordanians to South-East Asian 
populations (China, Chinese-Taiwanese, and 
Philippines) and Australian Aborigines. In the 
case of CYP2C19*3 allele, a lower distribution as 
in Jordanians have been found in European, 
North and South America, Africa, and some 
South-East Asian ethnic groups. Compared to 
the Jordanian population, a significantly higher 
allelic frequency of CYP2C19*3 allele was found 
in East-South Asian ethnic groups (China, 
Chinese-Taiwanese, Philippines, Japan and 
Korea), Australian Aborigines and Oceanians (p 
< 0.05). In this study, no statistical analysis was 
carried out for CYP2C19*4, *5, and *6 variants 
due to the absence of data for most of the 




Various studies indicated the genetic basis for 
interethnic and inter-individual variability in the 
metabolism of CYP2C19 substrates [20,21]. This 
leads to dividing individuals according to their 
CYP2C19 genotype and the associated 
CYP2C19 enzyme activity into four categories: 
Extensive, Intermediate, Poor and Ultrarapid 
metabolizers, according to individuals' response 
to drug therapy [6]. 
 
The distribution of CYP2C19*2 allele in the 
Jordanian population is consistent with the 
relatively high frequency of CYP2C19*2 allele 
worldwide [22], suggesting that CYP2C19*2 was 
present in humans way before the separation of 
humans into different distinctive populations [23]. 
However, the higher frequency of such variant in 
the Jordanian population compared to some 
regional countries such as Saudi Arabia, Egypt, 
Gaza Strip (Palestine), and Turkey [19] may be 
hypothesized to be the result of emigration and 
admixture between the native Jordanians and 
different populations such as the Circassians, 
Palestinians, Syrian, Iraqi, Lebanese, Egyptians 
and other ethnic Arab populations. On the other 
hand, the distribution of CYP2C19*3 allele in the 
Jordanian population was found to be similar to 
its distribution within the international populations 
except the south-East Asians, Australian 
Aborigines and Oceanians [19], suggesting that 
this allele may be specific to these populations 
and that it occurred quite recently, after the 
separation of Caucasian and Oriental groups 
[23,24]. 
 
Limitations of the study 
 
One major limitation of the current study is the 
scarce of information regarding CYP2C19 allele 
frequencies in Arab populations in order to make 
any kind of comparison. In addition, allele 
frequencies of CYP2C19*4, *5 and *6 in other 
populations are also lacking which made it 
impossible to draw any conclusion regarding 
these genotypes. 
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Jordan 260 0.3365 - 0.0077 - 
Europe 
Faroe Islands 310 0.188 0.00001 0.0000 0.1406 
Denmark 239 0.16 0.00001 0.0000 0.1747 
Germany 328 0.159 0.00001 0.0020 0.1947 
Croatia 200 0.15 0.00001 0.0000 0.1588 
Sweden 83 0.14 0.00001 0.0010 0.4183 
Russia 290 0.114 0.00001  0.0030 0.3011 
Italy 360 0.111 0.00001 0.0000 0.0577 
French Caucasians 172 0.0013 0.00001 0.00003 0.1908 
Romania 200 0.137 0.00001 0.0000 0.1588 
Belgium 121 0.091 0.00001 0.0000 0.2704 
Portugal 153 0.13 0.00001 0.0000 0.2154 
North America 
European American 87 0.13 0.00001 0.0000 0.3498 
African American 75 0.25 0.0033 0.0000 0.3858 
Canadian Inuit 89 0.11 0.00001 0.0000 0.3443 
Canadian Native Indian 115 0.191 0.00001 0.0000 0.2826 
South America 
Colombia 189 0.087 0.00001 0.0000 0.1687 
Bolivia 778 0.078 0.00001 0.0010 0.0276 
Africa 
Tanzania 251 0.18 0.00001 0.0100 >0.999 
Ethiopia 114 0.14 0.00001 0.0300 0.1580 
Benin 111 0.13 0.00001 0.0000 0.2911 
Egypt 247 0.109 0.00001 0.0020 0.2482 
Zimbabwean 87 0.13 0.00001 0.0000 0.4123 
Venda 78 0.22 0.0005 0.0000 0.3759 
Asia 
Saudi Arabia 97 0.15 0.00001 0.0000 0.3236 
Palestine (Gaza Strip) 200 0.0577 0.00001 0.0288 0.1352 
Jewish Israel 140 0.15 0.00001 0.0100 0.2359 
Iran  200 0.14 0.00001 0.0000 0.1568 
Turkey 404 0.12 0.00001 0.0040 0.3424 
China 121 0.455 0.784 0.0450 0.0276 
Chinese-Taiwanese 63 0.32 0.084 0.0500 0.032 
Philippines 52 0.39 0.5069 0.0800 0.0017 
North India 121 0.297 0.0092 0.0000 0.2704 
Japan 217 0.274 0.0002 0.1080 0.00001 
Korea 103 0.209 0.00001 0.1170 0.00001 
Australia and Oceania 
Australian Aborigines 227 0.355 0.0568 0.1430 0.00001 
Vanuatu + other pacific 
ocean islands 
5538 0.633 0.00001 0.1440 0.00001 




Earlier studies indicate that CYP2C19 
polymorphic nature plays a crucial role in the 
pharmacokinetics of drug therapy, thus 
suggesting the importance of CYP2C19 
genotyping prior to drug administration to 
achieve optimal dosage adjustment and cost-
effective therapy. The findings of this study confirm 
the importance of CYP2C19 genotyping prior to drug 
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